Asimov Achieves 10x Improvement in Lentiviral Production, Launches New Stable Cell Line Development Service

BOSTON--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development service. There are now two ways for customers to access Asimov’s cell line technology to minimize cost and manufacturing risk, depending on their needs: The LV Edge Packaging System, launched earlier this year, which enables a single plasmid transfection that achieves E8 TU